| 摘要 |
Pyrimidine-cyanoguanidine compounds Formula (I) and its pharmaceutically acceptable acid addition salts wherein R1 is hydrogen or methyl; R2 is C1-C6 alkyl, C2-C6 alkenyl, C21-C6 alkynyl, C3-C5 cycloalkyl, C3-C5 cycloalkenyl, hydroxy methyl, methoxy C1-C5 alkyl, or R1 and R2 are combined to form a C3-C6 carbocyclic ring; R3 and R4 are each independently selected to be hydrogen, C1-C4 alkyl, F. Cl, Br, I or CF3; R5 is hydrogen, F or Cl; R6 is hydrogen, -NH2, -NHCH3, -NHC2H5, -NHCH(CH3)2, -N(CH3)2, -N(C2H5)2, NH(CH2)m-OC1-C3 alkyl (where m is 2 or 3), -NHC(O)C1-C3 alkyl, Cl or Br, and n is 0 or 1. The compounds of Formula I are potassium channel blockers useful in the treatment of cardiovascular disorders such as congestive heart failure and hypertension and as a diuretic.
|
